Risk stratification and outcome in patients who underwent alloHCT (n = 504). (A) Comparison of outcome in patients stratified according to either ELN17 or ELN22. (B) Outcome of patients with MR gene mutations compared with patients with TP53 mutations within the ELN22 adverse-risk category. (C) Comparison of prognostic discrimination as assessed by time-dependent ROC curves for OS between ELN17 and ELN22.